Climadinon Tablets, coated, No. 60 (15 x 4)

In stock: 1
$63.72

Composition

Active ingredients: 1 tablet contains 20 mg of dry extract of black cohosh rhizome (Cimicifuga rhizome) (5–10:1), equivalent to 2.8 mg of native extract (extraction solvent: 58% ethanol (v/v));

Inactive ingredients: lactose monohydrate; potato starch; magnesium stearate; calcium hydrogen phosphate dihydrate; talc, titanium dioxide (E 171); yellow iron oxide (E 172); red iron oxide (E 172); polyethylene glycol 6000; ammonium methacrylate copolymer.

Dosage Form

Film-coated tablets.

Main physical and chemical properties: round, biconvex, terracotta-colored film-coated tablets with a smooth surface.

Pharmacotherapeutic group

Agents used in gynecology. Black cohosh rhizomes. ATC code G02CX04.

Pharmacological Properties

Pharmacodynamics. A herbal medicinal product for the treatment of premenopausal and menopausal disorders.

Black cohosh extract has a positive effect on the autonomic nervous system and reduces the severity of psychoemotional disorders during menopause. Use of the drug helps alleviate or completely eliminate symptoms of the condition during the premenopausal and menopausal periods, including hot flashes and excessive sweating.

Pharmacokinetics. No data available.

Indications

Neurovegetative disorders during menopause (hot flashes, excessive sweating, sleep disturbances, increased irritability, mood swings, apathy).

Contraindications

Individual hypersensitivity to the active ingredient or to other components of the drug. Estrogen-dependent tumors.

Interactions with Other Medications and Other Types of Interactions

When taken concomitantly with estrogens, Klimadinon® may enhance their effects (see the “Special Instructions for Use” section of the package insert).

Special Considerations for Use

Patients with a history of liver dysfunction should use this medication with caution. Liver function tests should be performed in these patients. If signs of liver damage appear (excessive fatigue, loss of appetite, yellowing of the skin and eyes, severe upper abdominal pain with nausea and vomiting, or dark urine), discontinue use of Klimadinon® and seek immediate medical attention.

In the event of menstrual irregularities or the resumption of menstruation, as well as in cases of prolonged menstruation or other complaints arising during treatment, consult a doctor to review the treatment regimen.

Women of reproductive age must use effective contraception.

Do not use Klimadinon® without consulting a doctor if the patient is already taking female sex hormones (estrogens).

If symptoms worsen while taking Klimadinon®, consult a doctor.

There is insufficient data to provide specific dosage recommendations for patients with impaired kidney or liver function. This medication contains lactose; therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it.

Note for patients with diabetes mellitus: 1 tablet contains an average of 0.01 bread unit (BU).

Use During Pregnancy or Breastfeeding. The safety of black cohosh during pregnancy has not been established; therefore, Klimadinon® should not be used during this period.

Due to the lack of data on whether the drug or its metabolites pass into breast milk, a risk to infants cannot be ruled out. Therefore, this medication should not be used while breastfeeding.

Effect on the ability to drive or operate machinery: Has no effect.

Dosage and Administration

Unless otherwise prescribed by a doctor, women during menopause should take 1 tablet twice daily (in the morning and in the evening).

Tablets should be swallowed whole without chewing and taken with a sufficient amount of liquid. Do not take a double dose if a dose is missed.

The duration of treatment is determined by the doctor on an individual basis. If symptoms do not subside during treatment, consult a doctor.

Do not use this medication for more than 6 months without consulting a doctor.

Children

This medication should not be given to children.

Overdose

There are no known cases of overdose with this medication.

If doses exceeding the recommended amounts are taken, inform your doctor so that appropriate measures can be taken. In case of overdose, symptomatic treatment should be provided.

Side Effects

When using medications containing black cohosh, cases of gastrointestinal disorders (including dyspepsia, diarrhea, nausea, and vomiting), allergic reactions (including skin rashes, itching, and hives), facial swelling, and peripheral edema. Hepatotoxic reactions (including hepatitis, jaundice, and abnormal liver function test results) have been associated with the use of products containing cimicifuga. There have been reports of breast tenderness and menstrual-like bleeding.

If any adverse reactions occur, discontinue use of the medication and consult a doctor.

Shelf life

4 years.

Do not use after the expiration date printed on the package.

The expiration date indicates that the product may be used until the last day of the specified month.

Storage Conditions

Store in the original packaging at a temperature not exceeding 30 °C, out of the reach of children.

Packaging

15 tablets per blister; 4 blisters No. 60 (15×4) per cardboard box.

Dispensing Category

Available without a prescription.

Manufacturer

Bionorica SE.

Manufacturer’s location and address of operations / applicant’s location and representative’s address.

Kerschensteiner Straße, 11–15, 92318, Neumarkt, Germany /

Kerschenstеіnerstrasse, 11-15, 92318 Neumarkt, Germany.

Contact information for the manufacturer’s representative in Ukraine, Bionorica LLC:

phone: 044 521 86 00; fax: 044 521 86 01, info@bionorica.ua